Nguyen ST, Bain AM, Bedimo RG, Hall RG, Busti A. Acute elevation of triglycerides after initiation of fosamprinavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. J Clin Lipid 2008;2(5):398-400

Busti AJ, Bain AM, Hall RG, Bedimo RG, Leff RD, Meek C, Mehkvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51(6):605-10. PMID: 18520949

Hall RG, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vanomycin dosing – emphasis on obesity. Am J Med 2008;121:515-8. PMID: 18501233

Burgess DS, Hall RG. Simulated comparison of ciprofloxacin and levofloxacin pharmacodynamics against Pseudomonas aeruginosa using healthy volunteer pharmacokinetic and 2002 minimum inhibitory concentration (MIC) data, Clin Ther 2007;29(7):1421-7. PMID: 17825693

Maclayton DO, Hall RG. Pharmacologic options for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. Ann Pharmacother 2007;41:235-44. PMID: 17299012

Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004;24(12):1732-47. PMID: 15585441

Burgess DS, Hall RG. In vitro activity of parenteral β-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum β-lactamase producing klebsiella pneumonia. Int J Antimicrob Agents 2004;24:48-52. PMID: 15225861

Burgess DS, Hall RG. In vitro activity of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumonia. Diagn Microbiol Infect Dis 2004;49(1):41-6. PMID: 15135499

Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE. Outcomes of patients infected with extended-spectrum beta-lactamase (ESBL) producing bacteria at a university hospital. Pharmacotherapy 2003;23(10):1232-7. PMID: 14594340

Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003;46(2):131-7. PMID: 12812717

Books and/or Chapters:
Hall RG. Nosocomial Pneumonia. In: Cheng JWM, Chessman KH, Hume AL et al., eds. Pharmacotherapy Self-Assessment Program, 6^th ed. Infectious Diseases Module. Lenexa, KS: American College of Clinical Pharmacy;2008:109-26.

Burgess DS & Hall RG. Aztreonam. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial Therapy and Vaccines.  2^nd ed. Pittsburgh, PA: ESun Technologies, LLC;2005:45-54 (Vol. 2).

Presentations (National, State and Local):

State & Local Level
“Starting with the End in Mind: Empiric Therapy for Patients with Hospital-Acquired or Healthcare-Associated Pneumonia” at the Texas Society of Health Systems Pharmacists Annual Meeting; Austin, Texas, April 2009.

“Surviving the Raging Sea of Antimicrobial Resistance” at the Texas Society of Health Systems Pharmacists Annual Meeting; Dallas, Texas, April 2008.

“New Weapons of Mass Destruction Against Community-Acquired Pneumonia” at the 9^th Annual Infectious Diseases Pharmacotherapy Conference; San Antonio, Texas, November 2005.

“Management of Problematic Gram-Negative Pathogens” at the Oklahoma Society of Health Systems Pharmacists Meeting; Oklahoma City, Oklahoma, April 2005.

“Antifungal Therapy in the A.D. (After Deoxycholate) Era” at the Texas Society of Health Systems Pharmacists 57^th Annual Seminar; Austin, Texas, April 2005.

“Fluoroquinolone Use: Is Too Much of a Good Thing a Bad Thing?” at the Texas Society of Health Systems Pharmacists 56^th Annual Seminar; Houston, Texas, April 2004.

(Last updated: 2/9/2009)